Published by Coherent Market Insights
Posted on September 28, 2021
Cancer Biomarkers Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Cancer Biomarkers Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/175
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.
The Global Cancer Biomarkers Market was valued US$ 33.7 billion in 2019 and is projected to exhibit a CAGR of 14.2% over the forecast period (2019–2026).
Growing prevalence and incidence of various types of cancers, and the increasing need for early diagnosis of cancers are the major factors driving growth of the global cancer biomarkers market over the forecast period. Continuous research and development activities and technological advancements in cancer treatment have led to introduction of better and affordable biomarkers. For instance, according to a study published in the Cell Metabolism Journal, in March 2018, a team of Australian researchers found a unique metabolic marker which can detect adenocarcinomas (a form of lung cancer). These metabolic biomarkers respond to immunotherapies and offer simple, non-invasive blood tests for early detection of lung cancer.
Browse 35 Market Data Tables and 33 Figures spread through 160 Pages and in-depth TOC on “Cancer Biomarkers Market, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer and Other Cancers), by End User (Hospitals, Academic and Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories) – Global Forecast to 2025”
In February 2018, researchers at Georgetown-Lombardi Comprehensive Cancer Center identified biomarkers which can use liquid biopsies to predict response to cancer treatment and help in identifying increasingly specific subsets of GI cancers to make treatment decisions. According to data published in the European Journal of Breast Health, in October 2017, body fluid tests can be used for early detection of new or recurrent breast cancer. This new approach includes tissue testing and body fluid analysis of individuals diagnosed with breast cancer, for more effective cancer treatment. Moreover, manufacturers are focusing on developing new cancer biomarkers, which would aid in early diagnosis of cancer and are used for oncology research studies. For instance, in November 2016, Oxford Cancer Biomarkers Ltd. introduced ColoTox test for predicting risk of toxicity with cancer chemotherapy tests. In December 2015, Olink Bioscience introduced Proseek Multiplex Oncology II96x96: 92 human protein biomarker panel for oncology research.
Key takeaways of the cancer biomarkers market:
The global cancer biomarkers market is expected to expand at a CAGR of 14.2% during the forecast period (2017–2025), owing to increasing prevalence and incidence of cancer and growing demand for early diagnosis of cancer. For instance, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012. Moreover, India, China and other East and Central Asian countries accounted for nearly half of world’s new cancer cases and deaths, in 2017. In addition, according to the same source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4 million cancer deaths, in less developed regions.
Protein biomarkers segment holds a major share in the market due to its extensive use in analyzing protein concentration in blood, tissue, urine, and other body fluids for early cancer detection.
Based on cancer type, liver cancer segment holds largest revenue share in the market due to increasing number of liver cancer biomarkers in the market and their ability for efficiently diagnose early stage liver cancer
Among end users, diagnostic laboratories segment holds the largest market share owing to provision of advanced services for testing and research
Buy This Premium Report Of Cancer Biomarkers Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/175
In this study, the years considered to estimate the market size of Cancer Biomarkers are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Cancer Biomarkers Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Cancer Biomarkers Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Cancer Biomarkers Market: Focusing Long-Term Professional Industry And Making New Commitments To The Sustainable Future appeared first on Gatorledger.
Cancer Biomarkers Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Cancer Biomarkers Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/175
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.
The Global Cancer Biomarkers Market was valued US$ 33.7 billion in 2019 and is projected to exhibit a CAGR of 14.2% over the forecast period (2019–2026).
Growing prevalence and incidence of various types of cancers, and the increasing need for early diagnosis of cancers are the major factors driving growth of the global cancer biomarkers market over the forecast period. Continuous research and development activities and technological advancements in cancer treatment have led to introduction of better and affordable biomarkers. For instance, according to a study published in the Cell Metabolism Journal, in March 2018, a team of Australian researchers found a unique metabolic marker which can detect adenocarcinomas (a form of lung cancer). These metabolic biomarkers respond to immunotherapies and offer simple, non-invasive blood tests for early detection of lung cancer.
Browse 35 Market Data Tables and 33 Figures spread through 160 Pages and in-depth TOC on “Cancer Biomarkers Market, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer and Other Cancers), by End User (Hospitals, Academic and Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories) – Global Forecast to 2025”
In February 2018, researchers at Georgetown-Lombardi Comprehensive Cancer Center identified biomarkers which can use liquid biopsies to predict response to cancer treatment and help in identifying increasingly specific subsets of GI cancers to make treatment decisions. According to data published in the European Journal of Breast Health, in October 2017, body fluid tests can be used for early detection of new or recurrent breast cancer. This new approach includes tissue testing and body fluid analysis of individuals diagnosed with breast cancer, for more effective cancer treatment. Moreover, manufacturers are focusing on developing new cancer biomarkers, which would aid in early diagnosis of cancer and are used for oncology research studies. For instance, in November 2016, Oxford Cancer Biomarkers Ltd. introduced ColoTox test for predicting risk of toxicity with cancer chemotherapy tests. In December 2015, Olink Bioscience introduced Proseek Multiplex Oncology II96x96: 92 human protein biomarker panel for oncology research.
Key takeaways of the cancer biomarkers market:
The global cancer biomarkers market is expected to expand at a CAGR of 14.2% during the forecast period (2017–2025), owing to increasing prevalence and incidence of cancer and growing demand for early diagnosis of cancer. For instance, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012. Moreover, India, China and other East and Central Asian countries accounted for nearly half of world’s new cancer cases and deaths, in 2017. In addition, according to the same source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4 million cancer deaths, in less developed regions.
Protein biomarkers segment holds a major share in the market due to its extensive use in analyzing protein concentration in blood, tissue, urine, and other body fluids for early cancer detection.
Based on cancer type, liver cancer segment holds largest revenue share in the market due to increasing number of liver cancer biomarkers in the market and their ability for efficiently diagnose early stage liver cancer
Among end users, diagnostic laboratories segment holds the largest market share owing to provision of advanced services for testing and research
Buy This Premium Report Of Cancer Biomarkers Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/175
In this study, the years considered to estimate the market size of Cancer Biomarkers are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Cancer Biomarkers Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Cancer Biomarkers Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Cancer Biomarkers Market: Focusing Long-Term Professional Industry And Making New Commitments To The Sustainable Future appeared first on Gatorledger.
Explore more articles in the Research Reports category
